If you’ve already registered, please click here to log in to the webcast.

This webcast discusses the tremendous translational and clinical progress in CAR T cell therapy and provides an overview of its limitations and challenges. We will summarize developments in the use of chimeric antigen receptors (CARs) - engineered, synthetic receptors redirecting lymphocytes to recognize and kill cancer cells. CARs have revolutionized cancer therapy, resulting in several FDA approvals, nevertheless, there are major limitations that need to be addressed to expand CAR T cell therapy safely to a broader patient population.

In this webcast, Marcela Maus (Massachusetts General Hospital) and Jan Joseph Melenhorst (Cleveland Clinic) will discuss recent developments in the CAR T cell space, including technical approaches to enhance specificity, potency and safety of the therapy, as well as pre-clinical and clinical studies that highlight the success and longevity of CAR T cells, but also showcase our need to better understand patient-monitoring and manage adverse events.